| 1 |
30088438 | Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. | 2018 Sep 1 |
3 |
| 2 |
24080214 | Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: a biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia. | 2014 Feb 15 |
4 |
| 3 |
15723262 | Biochemical modulation of cytarabine triphosphate by clofarabine. | 2005 Apr |
2 |
| 4 |
15935150 | A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells. | 2005 Jun 15 |
3 |
| 5 |
12060121 | In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. | 2002 Jun |
2 |
| 6 |
11243402 | Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells. | 2001 Jan |
2 |
| 7 |
11376564 | Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses. | 2001 May |
5 |
| 8 |
10355579 | All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation. | 1999 Mar |
3 |
| 9 |
9338077 | Ara-C: cellular and molecular pharmacology. | 1998 |
2 |
| 10 |
8547650 | Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. | 1996 Jan 1 |
3 |
| 11 |
9816215 | Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. | 1996 Apr |
1 |
| 12 |
7974627 | Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells. | 1994 Aug |
2 |
| 13 |
8174200 | Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. | 1994 |
3 |
| 14 |
8436210 | On the interaction between cytosine arabinoside and etoposide in vivo and in vitro. | 1993 Jan |
2 |
| 15 |
8481660 | Biochemical modulation of arabinosylcytosine for therapy of leukemias. | 1993 |
2 |
| 16 |
1884247 | Intracellular dCTP/ara-CTP ratio and the cytotoxic effect of ara-C. | 1991 |
1 |
| 17 |
2212834 | [Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C]. | 1990 Jul 20 |
9 |
| 18 |
2478221 | Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. | 1989 Nov 1 |
1 |
| 19 |
3115933 | Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity. | 1987 Aug |
1 |
| 20 |
3470578 | In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. | 1987 |
3 |
| 21 |
3669771 | Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. | 1987 Aug |
2 |
| 22 |
3980658 | Simultaneous determination of cytosine arabinoside, its nucleotides and metabolites by ion-pair high-performance liquid chromatography. | 1985 Jan 11 |
4 |
| 23 |
4012338 | Pharmacologically directed ara-C therapy for refractory leukemia. | 1985 Jun |
1 |
| 24 |
6576907 | Prediction of sensitivity to 1-beta-D-arabinofuranosylcytosine by the plateau level of its 5'-triphosphate in human lymphoblastic cell lines in vitro. | 1983 Jul |
1 |
| 25 |
7083175 | Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. | 1982 Jul |
3 |
| 26 |
7184462 | [Correlation between ara-C sensitivity and intracellular ara-C concentration in a cultured human lymphocyte model]. | 1982 Sep |
2 |
| 27 |
6937239 | Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. | 1980 Mar |
2 |